Most Read Articles
Pearl Toh, 6 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 19 Mar 2020
The assumption that children are less vulnerable to the coronavirus disease 2019 (COVID-19) compared to adults is not quite true and may even be dangerous, suggests a recent study.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
24 Mar 2020
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.

Atopic eczema ups fracture risk

12 Feb 2020

Fractures, particularly major osteoporotic fractures, are more likely to develop in people with atopic eczema, a recent study has found.

Researchers conducted a matched cohort study including 526,808 atopic eczema patients (58.4 percent female). The outcome of interest was the likelihood of sustaining major osteoporotic fractures in the hip, pelvis, spine, wrist and proximal humerus, compared with 2,569,030 healthy comparators (58.0 percent female). All participants were at least 18 years of age.

Fully adjusted Cox regression analysis found that the likelihood of developing any fracture was significantly higher in those with atopic eczema (hazard ratio [HR], 1.07, 99 percent confidence interval [CI], 1.05–1.09).

Disaggregating according to site of fracture revealed a similar effect of atopic eczema on wrist (HR, 1.06, 99 percent CI, 1.01–1.10), spinal (HR, 1.14, 99 percent CI, 1.06–1.23) and hip (HR, 1.06, 99 percent CI, 1.02–1.11) fractures. No such trend was apparent for pelvic and proximal humeral fractures.

Eczema severity likewise emerged as an important factor. For example, there was a 6-percent increase in the risk of spinal fracture in those with mild eczema (HR, 1.06, 99 percent CI, 0.96–1.17). In comparison, the risk increments in those with moderate and severe eczema were 22 percent (HR, 1.22, 99 percent CI, 1.10–1.36) and 109 percent (HR, 2.09, 99 percent CI, 1.66–2.65), respectively.

Severe atopic eczema also resulted in strong increases in the risks of pelvic (HR, 1.66, 99 percent CI, 1.26–2.20) and hip (HR, 1.50, 99 percent CI, 1.30–1.74) fractures.

Editor's Recommendations
Most Read Articles
Pearl Toh, 6 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 19 Mar 2020
The assumption that children are less vulnerable to the coronavirus disease 2019 (COVID-19) compared to adults is not quite true and may even be dangerous, suggests a recent study.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
24 Mar 2020
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.